ProShare Advisors LLC Has $73,000 Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC)

ProShare Advisors LLC increased its position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) by 83.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,283 shares of the company’s stock after buying an additional 9,204 shares during the period. ProShare Advisors LLC’s holdings in C4 Therapeutics were worth $73,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. lifted its position in C4 Therapeutics by 198.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,550,000 shares of the company’s stock worth $5,580,000 after acquiring an additional 1,030,000 shares during the last quarter. Wasatch Advisors LP lifted its position in C4 Therapeutics by 7.0% during the fourth quarter. Wasatch Advisors LP now owns 6,072,601 shares of the company’s stock worth $21,861,000 after acquiring an additional 395,233 shares during the last quarter. Millennium Management LLC lifted its position in C4 Therapeutics by 1,548.3% during the fourth quarter. Millennium Management LLC now owns 360,125 shares of the company’s stock worth $1,296,000 after acquiring an additional 338,277 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in C4 Therapeutics by 497.2% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 137,360 shares of the company’s stock worth $494,000 after acquiring an additional 114,360 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in C4 Therapeutics during the fourth quarter worth approximately $391,000. 78.81% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, UBS Group raised shares of C4 Therapeutics to a “hold” rating in a research report on Friday, February 14th.

C4 Therapeutics Stock Performance

C4 Therapeutics stock opened at $1.48 on Wednesday. The stock has a market capitalization of $105.09 million, a price-to-earnings ratio of -0.87 and a beta of 3.10. C4 Therapeutics, Inc. has a 52-week low of $1.09 and a 52-week high of $7.66. The stock’s 50 day moving average price is $1.42 and its two-hundred day moving average price is $2.73.

C4 Therapeutics (NASDAQ:CCCC) last issued its earnings results on Wednesday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.11. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The company had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $3.54 million. On average, equities research analysts forecast that C4 Therapeutics, Inc. will post -1.52 EPS for the current year.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.